hydroxyamphetamine

Trade name: paredrine

Small moleculeapproved

Approved

Jul 16, 1969

Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes. The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions. Hydroxyamphetamine hydrobromide is a component of FDA approved brand drug - Paremyd sterile ophthalmic solution (Hydroxyamphetamine hydrobromide, USP 1.0%, Tropicamide, USP 0.25%). Hydroxyamphetamine is an indirect-acting sympathomimetic, while tropicamide acts as a parasympatholytic. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 4 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1960s

Jul 16, 1969
Smith, Kline & French — Earliest FDA Approval
Jul 16, 1969
Pharmics — Marketing Organization
Jul 16, 1969
Smith, Kline & French — NDA Organization
Jul 16, 1969
Pharmics — NDA Secondary Org

1990s

Jan 30, 1992
Akorn, Inc. — Marketing Organization
Jan 30, 1992
Akorn, Inc. — NDA Secondary Org
Jan 30, 1992
Epic Pharma Llc — NDA Secondary Org

Indications

Approved for

Eye Diseases (approved 1992)

Mechanism of action

Adrenergic receptorAGONIST
Adrenergic receptor agonist

Combination products

paremy
with tropicamide

Approval history

approvedJul 16, 1969

Chemistry & pharmacology

Loading structure…

SMILES

CC(N)Cc1ccc(O)cc1

Mol. weight: 151.21 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Topical
Availability: Discontinued

Oral

Parenteral

Topical

Yes

Sources

Also known as

4-(2-aminopropyl)phenol
4-(2-aminopropyl)phenol
4-hydroxyamphetamine
4-hydroxyamphetamine
4-hydroxyamphetamine
dl-4-hydroxyamphetamine
dl-4-hydroxyamphetamine
dl-p-hydroxyamphetamine
dl-p-hydroxyamphetamine
hydroxyamfetamine
hydroxyamfetamine
hydroxyamfetamine
hydroxyamfetamine
hydroxyamfetamine hydrobromide
hydroxyamphetamide
hydroxyamphetamin
hydroxyamphetamine
hydroxyamphetamine
hydroxyamphetamine
hydroxyamphetamine
hydroxyamphetamine
hydroxyamphetamine
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hydroxyamphetamine hydrobromide
hyroxyamfetamine hydrobromide
hyroxyamfetamine hydrobromide
methyltyramine
oxamphetamine
oxamphetamine hydrobromide
oxamphetamine hydrobromide
para-hydroxyamphetamine
paredrine
paredrine
paredrine
paredrine

Organizations

Marketing (6)

Organization	Org type	Relationship	Date
Akorn, Inc.	For profit	MKTG	Jan 30, 1992
Akorn, Inc.	For profit	NDA2	Jan 30, 1992
Epic Pharma Llc	For profit	NDA2	Jan 30, 1992
Pharmics	For profit	MKTG	Jul 16, 1969
Pharmics	For profit	NDA2	Jul 16, 1969
Smith, Kline & French	For profit	NDA	Jul 16, 1969